Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ReceptorPAINT

Financiado

Cerrado

Imaging Receptomics as a tool for biomedical discovery

Targeting cell surface proteins to alter cellular behavior is a major aim of many therapeutics. Recently approved immunotherapeutic drugs trigger anti-tumor immunity by disrupting key cell surface proteins that guide immune cell i... ver más

31/03/2027

LMU MUENCHEN

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-04-30

ERC-2020-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

LMU MUENCHEN

1.60M€ | Lider

INERCO INGENIERIA TECNOLOGIA...

361.93K€ | Participante

MPG

750.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NANODIAGNOSTIC Super-resolution microscopy for immune checkpoint inhibitors... 150K€ Cerrado

NANODYNATCELLVATION Nano structural and dynamic events in the T cell activatio... 100K€ Cerrado

Immune-Image Immune Image Specific Imaging of Immune Cell Dynamics Using... 27M€ Cerrado

FNS-4-NAMOSAT Development of fluorescence nanospectroscopy to elucidate th... 195K€ Cerrado

PALMASSEMBLY Protein assembly From the molecular scale to the mesoscale... 2M€ Cerrado

DYNAFLUORS Dynamic Activatable Fluorophores 2M€ Cerrado

Duración del proyecto: 71 meses Fecha Inicio: 2021-04-30
Fecha Fin: 2027-03-31

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Targeting cell surface proteins to alter cellular behavior is a major aim of many therapeutics. Recently approved immunotherapeutic drugs trigger anti-tumor immunity by disrupting key cell surface proteins that guide immune cell interactions. Despite the cell surface representing a major site of drug action, its nanoscale organization remains poorly characterized. The main reason for this is largely due to technical limitations of current fluorescence and super-resolution imaging approaches, which do not allow high-throughput measurements of the spatial localization and interaction of hundreds of proteins with true single-protein- resolution on cell surfaces. We here propose to develop exactly such a disruptive capability by advancing recently developed DNA-PAINT microscopy to enable the visualization and quantification of all relevant cell surface proteins at single-protein-resolution. We will achieve this by innovating DNA-PAINT to enable isotropic 1-nm-resolution, develop DNA-based protein binders against all cell surface proteins, and devise multiplexing capabilities to resolve them with single-protein-resolution over large fields of view, reaching the ultimate goal of enabling Imaging Receptomics. We will then apply this to test the central hypothesis that surface protein architecture and patterning on immune and tumor cells dictates the outcome of their interactions. We will map the nanoscale organization of hundreds of key immunomodulatory surface proteins and their corresponding ligands on key interacting pairs of immune cells relevant to current immunotherapy approaches (dendritic cells and T cells), as well as tumor cells. This will yield fundamental insights into the molecular architecture of their interactions and potentially enable the future development of more refined pattern-based immunotherapeutics. Collectively, this highly multidisciplinary and novel approach has the potential to be ground-breaking across a range of research fields.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores